MedTrace Logo

Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty

NCT03825939 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2021-09-28

Study results available
· View outcomes & findings →

Summary

This research study aims to study the use of tranexamic acid (TXA) in total joint replacement (arthroplasty) of the hip (THR) and knee (TKR).

Conditions

  • Blood Loss

Interventions

DRUG

Intravenous Placebo

IV 0.9% sterile saline

DRUG

Intravenous Tranexamic Acid

1g TXA IVPB (intravenous piggyback)

Sponsors & Collaborators

Principal Investigators

  • Jan A Koenig, M.D. · Winthrop University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-21
Primary Completion
2016-07-26
Completion
2016-09-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03825939 on ClinicalTrials.gov